Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Powerful Demonstration: MTM May Be Counterpoint To Pricing Complaints

This article was originally published in RPM Report

Executive Summary

A proposed “enhanced” model for Medication Therapy Management in Medicare Part D draws rave reviews from a House subcommittee. The prospect of using medication better to lower overall costs is a great counterpoint to headlines about excessive drug prices.

You may also be interested in...



Medicare Part D ‘Enhanced MTM Model’ Saves $325m In First Year

US Centers for Medicare and Medicaid Services announces first-year results from its medication therapy management model, intended to optimize prescription drug use among Medicare beneficiaries.

Clear Messages From Part D: Managed Care Learns to Work With Retail Pharmacists

Medicare drug plans and retail pharmacy groups are working together to clean up the mess that plagued the launch of Part D. The manufacturers should pay attention: the result may be new force in drug selection and adherence.

The TRIPS Trap: Industry’s Delicate Challenge Responding To Waiver Push

Biopharma companies are understandably upset by the Biden Administration’s decision to support a waiver of intellectual property protections on COVID vaccines. But over-reacting may only make matters worse.

Topics

UsernamePublicRestriction

Register

PS079783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel